Concepedia

Lei Xu

LX

Statistics

Publications

89

Citations

8.1K

H-Index

34

Active since

1999

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Shanxi University of Finance and Economics

Jishou University

China Medical University

Chinese Academy of Agricultural Sciences

Lei Xu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, cancer research, and oncology.

ORCID

Top concepts

Publications per year

1999–2025

89

Publications

89

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.4K citations · Full text

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord et al. · Journal of Clinical Oncology · 2019 · 1K citations · Full text

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

Itamar Raz, M Hanefeld, Lei Xu et al. · Diabetologia · 2006 · 614 citations · Full text

, , +5

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier et al. · Journal of Clinical Oncology · 2022 · 457 citations · Full text

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín et al. · Journal of Thoracic Oncology · 2019 · 427 citations · Full text

1–5 of 89